Dr. Kinter is currently Senior Director: Regulatory Toxicology and Head: Toxicological Operations, Safety Assessment (US) at AstraZeneca Pharmaceuticals in Wilmington, Pennsylvania, and manages preclinical safety programs conducted in support of AstraZeneca’s pharmaceutical clinical development activities in the US. Dr. Kinter has been engaged in pharmaceutical research and development and comparative physiology/medicine for 28 years and is an expert in the area of cardiovascular-renal function assessments in animals.
Dr. Kinter received his doctorate in Medical Physiology from Harvard University (1978) where he initiated his professional interests in cardiovascular/renal physiology and pharmacology. Since 1981 he has held positions of increasing responsibility in pharmaceutical R&D, serving with SmithKline Beecham, Sterling Winthrop, Nycomed Amersham, and AstraZeneca. Dr. Kinter is a Diplomat of the American Board of Toxicology, Fellow of the Academy of Toxicological Sciences, Professor of Physiology (Adjunct), University of Pennsylvania School of Medicine, and an author of over 100 research manuscripts and book chapters in basic and applied physiology, pharmacology, and toxicology. He regularly reviews research manuscripts for several pharmacology and toxicology journals. Dr. Kinter is a founder and Past President of the Safety Pharmacology Society and the first recipient of the Society’s Career Distinguished Service Award. Dr Kinter was until recently Chair of the PhRMA Preclinical Safety Leadership Committee (formerly DruSafe), and is currently an inaugural member of the PhRMA Clinical and Preclinical Development Committee.
Dr. Kinter has also held leadership positions on Boards of Directors and Trustees of local community not-for-profit organizations.